A Diagnosis of Allergic Contact Dermatitis (ACD) must be strongly considered for patients who present with a chronic or recurrent rash. When the rash is in a clothing (or textile) distribution ...

If you’ve ever fallen down a #SkinTok rabbit hole (guilty), you’ve probably heard of atopic dermatitis (AD ... to limit how much you sweat during exercise and change out of damp clothing ASAP after ...

Eczema is a group of conditions that make your skin inflamed or irritated. The most common type is atopic dermatitis. Conditions That Can Look Like Eczema but Aren’t Your dermatologist or ...

When people talk about eczema, they usually mean atopic dermatitis — its most common ... trigger your eczema including dry weather or air, clothing fibers, skin and makeup products, pollutants ...

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the international CorEvitas ...

AMSTERDAM, Netherlands — For patients with atopic dermatitis (AD) who responded to the anti-interleukin (IL)-13 monoclonal antibody lebrikizumab in the pivotal trials, the level of response ...

But when should you be concerned that it might be atopic dermatitis? Atopic dermatitis, often referred to as eczema, is a ...

Eli Lilly revs up immunology engine as Olumiant cruises toward coveted alopecia green light “Patients still struggle to control their moderate-to-severe atopic dermatitis with currently ...

People with moderate-to-severe atopic dermatitis, the most common form of eczema, don’t always get adequate relief from topical treatments like steroid creams and ointments. Now they have a new ...

(RTTNews) - Arcutis Biotherapeutics Inc.'s (ARQT) ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of atopic dermatitis in individuals regardless of race ...

The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older with moderate-to-severe atopic dermatitis. The approval ...

The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older with moderate to severe atopic dermatitis (AD). The FDA approved ...